The Trump administration’s move to cancel a slew of federal contracts at Harvard University has sparked an internal clash over the impact on medical research intended to help veterans, including projects involving suicide prevention, toxic particle exposure and prostate cancer screening, according to emails reviewed by The New York Times.
The dispute among officials at the Department of Veterans Affairs has focused in part on a collaboration with Harvard Medical School to develop a predictive model to help V.A. emergency room physicians decide whether suicidal veterans should be hospitalized, according to the records.
Canceling that contract would result in “more veteran suicides that could have been prevented,” Seth J. Custer, an official in the V.A.’s Office of Research and Development, wrote in a May 8 email asking leaders at the agency to reverse their decision. But John Figueroa, a longtime private industry health care executive and a senior adviser to Doug Collins, the veterans affairs secretary, said that researchers at other institutions could do the work instead.
Peter Kasperowicz, a V.A. spokesman, said that the department’s research contracts with Harvard were “under review.” He said the goal of the review was to ensure that “the projects best support the Trump administration’s veterans-first agenda.”
Mr. Custer declined to comment. In a brief telephone interview, Mr. Figueroa said the V.A. was examining “every contract” it had issued. A White House spokeswoman declined to comment. So did a spokeswoman for Harvard.
The tensions inside the V.A. over the Harvard contracts demonstrate how President Trump’s use of research funds as leverage in his broader pressure campaign on universities carries political risks. Mr. Trump and other Republicans have courted veterans as a key political constituency, and Mr. Collins has repeatedly promised that veteran care would not be affected, even as he enacts major cost-cutting measures and other changes.
